Logos Global Management LP Aligos Therapeutics, Inc. Transaction History

Logos Global Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.87 - $2.11 $870,000 - $2.11 Million	1,000,000 New	1,000,000 $870,000
Q1 2022 May 16, 2022	SELL	$2.08 - $12.2 $6.47 Million - $38 Million	-3,112,785 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$11.48 - $17.69 $13.2 Million - $20.3 Million	1,150,000 Added 58.59%	3,112,785 $36.9 Million
Q3 2021 Nov 15, 2021	BUY	$14.57 - $17.72 $25.5 Million - $31 Million	1,750,000 Added 822.43%	1,962,785 $30.4 Million
Q2 2021 Aug 16, 2021	SELL	$20.3 - $33.6 $5.35 Million - $8.86 Million	-263,762 Reduced 55.35%	212,785 $4.34 Million
Q1 2021 May 17, 2021	SELL	$19.1 - $34.94 $2.48 Million - $4.54 Million	-130,001 Reduced 21.43%	476,547 $10.8 Million
Q4 2020 Feb 16, 2021	BUY	$13.2 - $32.74 $8.01 Million - $19.9 Million	606,548 New	606,548 $16.8 Million

227K

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $1.3B
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

Get notified when there are updates to the investment portfolio of Logos Global Management LP, based on Form 13F filings with the SEC.

Stay updated on Logos Global Management LP with notifications on news.